Purchase this article with an account.
J. P. Owen, T. Purcell, L. Cheng, D. Schanzlin; Effect of Topical Cyclosporine 0.05% on Enhancement Rates in Myopic LASIK Patients. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3367.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine if the postoperative use of cyclosporine ophthalmic emulsion 0.05% (Restasis ®) reduces the enhancement rate and improves visual outcomes of myopic LASIK patients.
A retrospective analysis was conducted on 221 myopic eyes of 126 patients who had LASIK with a single surgeon (djs). All eyes had a refractive error between plano and -6.5 dioptors with up to 2.5 dioptors of cylinder. One hundred nine eyes used topical cyclosporine twice-daily for one month as part of their post-operative protocol and 112 eyes did not use cyclosporine. All patients were treated on the VISX S4 CustomVue laser or the Allegretto excimer laser with their corneal flap created by a femtosecond laser (Intralase; Irvine, CA). Outcome variables included enhancement rates and uncorrected visual acuity (UCVA) at 1 day and 3 months postoperatively.
Eyes treated with topical cyclosporine were significantly less likely to require enhancement than eyes not treated with cyclosporine [2.8% (3/109) with cyclosporine and 9.8% (11/112) without cyclosporine (P=.031). At month 3, eyes treated with cyclosporine also had significantly better mean UCVA than eyes not treated with cyclosporine (P=.033).
Postoperative topical cyclosporine ophthalmic emulsion 0.05% reduced the enhancement rate and improved visual outcomes in myopic LASIK patients.
This PDF is available to Subscribers Only